Radioimmunoassay kits prepared in the Chelsea Hospital for Women for follicle stimulating hormone (FSH) and luteinising hormone (LH) have been used in 26 UK laboratories for over 2 years. Data from the UK External Quality Assessment Schemes for FSH and LH have been used to provide an independent assessment of the performance of these kits over a 12-month period.
Improved performance of plasma gonadotrophin assays using common reagents and assay protocols: evidence from the UK External Quality Assessment Scheme MARGARET Radioimmunoassay kits prepared in the Chelsea Hospital for Women for follicle stimulating hormone (FSH) and luteinising hormone (LH) have been used in 26 UK laboratories for over 2 years. Data from the UK External Quality Assessment Schemes for FSH and LH have been used to provide an independent assessment of the performance of these kits over a 12-month period.
For both analytes, users of the kits were found to have: (I) a low variability of the bias, implying good within-laboratory, between-assay precision;
(2) a lower between-laboratory. within-sample geometric coefficient of variation than users of 'own' methods, implying better between-laboratory agreement; (3) method bias that did not differ significantly from laboratories using 'own' method protocols.
This survey indicates that a non-commercial organisation can produce immunoassay kits that improve the quality of FSH and LH assays generally available.
Major limitations to the wider use of hormone immunoassay techniques in hospital laboratories in the United Kingdom arc the continued supply of reagents and availability of well-tried assay protocols. Reagents need to be of high quality, well characterised. and matched together with a protocol designed to give accurate and precise results within appropriate constraints of practicality and cost. In the absence of such supply, samples obtained locally have to be sent to a regional or supraregional laboratory. This may result in the inefficiency associated with analyses being carried out at a distance from the patient and a diminution of local expertise in the performance and interpretation of assays.
One alternative approach is the provision from one centre of certain critical reagents, e.g. pure antigen for labelling. Though inexpensive and easy to organise, this has been found to have disadvantuges-s-the necessary level of expertise and facilities (e.g. for iodination) may Correspondence: Professor S L Jcffcontc. not be available; inevitably there will be between-laboratory variability in the way in which reagents are handled and used; and the provision of materials in this form can be wasteful of scarce reagents.
A second possibility is the purchase of commercial kits which are frequently (though not invariably) well designed and packaged and subjected to stringent quality-control procedures. Assuming adequate reproducibility and freedom from bias (an assumption which may be unwarranted), the main disadvantage of the commercial kit is its price-s-around £l'()() per assay tube.
The third approach, and the one adopted here in the case of the kits for FSH and LH produced by the Chelsea Hospital for Women (CHW kits), is to combine the advantages of the other two to produce a kit that is well designed, packaged and subjected to quality control. at a cost that is a fraction of that of commercial kits. The Chelsea kits have the added advantage that they are produced in a National Health Service laboratory using the 179 assays for patient management and clinical research.
We have previously reported on our internal evaluation of the method's imprecision, reproducibility and bias and on the results of a small multi-centre collaborative trial. I The CHW kit has now been in use for over 2 years and we here report an evaluation of its performance in 26 centres over 1 year. The data used for this evaluation are derived from the UK External Quality Assessment Scheme (EQAS) for FSH and LH, which provides an objective comparison of performance with laboratories using their own method protocols and those using commercial kits. Data from the latter group are not included in the comparison owing to the relative small numbers using commercial kits in these schemes.
Laboratory method groups CHELSEA KIT USERS (CHW KITS)
The methods for luteinising hormone (LH) and follicle stimulating hormone (FSH) were as described previously.' The kits are packaged together with method protocols and sufficient materials to assay 150 test samples (tubes) of each hormone, i.e. 300 tubes per kit, and are distributed every 4 weeks at a cost of £20·(}() per kit. There were 26 regular users over the period studied; of these between 22 and 24 returned sufficient data to EQAS for evaluation.
'OWN' METHOD USERS Thirty laboratories used their own method protocols. The majority of these used radiolabelled FSH and LH supplied from the Chelsea Hospital for Women; some were similarly supplied with antiserum, working standard and, in some cases, separation materials. Laboratories using CHW tracers did not differ significantly in their variability of the bias (Mann-Whitney U test) or cumulative mean bias from laboratories using 'own' methods with other tracer preparations. For the purpose of this comparison therefore, CHW tracer users are not separately identified in the 'own' method groups.
UK External Quality Assessment Schemes
In these schemes, the participants are sent five samples for assay each month. Results, expressed in terms of IRP 78/549 for FSH and 68/40 for LH, are returned to the EQAS centre where the following statistics are calculated.
ALL-LABORATORY TRIMMED MEAN (ALTM) AND GEOMETRIC COEFFICIENT OF VARIATION (GCV)
All results are transformed into their logarithms and ranked. The lowest and highest 5% of results (rounded up to the nearest even number) are excluded and play no part in the calculations of mean value and dispersion of values, but are not necessarily outliers and are therefore retrieved for later calculation of individual bias and variability of the bias. The trimmed mean and trimmed SO are calculated by the method of Healy (1979).2 The SO refers only to the log values-its antilog is not a measure of dispersion of the raw results. To get a measure of this dispersion, the geometric coefficient of variation (GCY) is calculated.:'
Results reported as 'less than' or 'more than' are excluded from the calculations. Results lying outside the limits ALTM±3 SD are classed as between-laboratory outliers.
The ALTM for each sample is recalculated each time that late or amended results are received.
MEAN BIAS AND VARIABILITY OF THE BIAS
The bias is calculated by subtracting the log of the ALTM from the log of the laboratory's result. All usable results within a 6-month window are included. The biases are ranked and trimmed, and the mean and SO calculated as above. The number of within-laboratory outliers is then determined.
An important requirement of any external quality-assessment scheme is that the target value of each pool (here the ALTM) should be accurate. Although this is difficult to demonstrate rigorously, recovery experiments performed through the schemes have provided some evidence on this point. Thus addition of 4 U/L of FSH (IRP 78/549) or LH (68/40) to pooled serum samples from hypopituitary patients (presumed analyte free) gave ALTMs which were 105% and 135% respectively of the theoretical level. Following the addition of 30 U/L of FSH or LH to normal serum, and correcting for concentration of endogeneous hormone, the increments in the AL TM were 98·7 and 119·5% respectively of the theoretical values. Thus the limited data available suggest that the AL TM is probably accurate in the FSH scheme, but may overestimate the true value in the LH scheme. For all usable pools distributed during a 12-month period, between-laboratory geometric CVs were calculated for the CHW and 'own' method groups. Mean geometric CVs within concentration ranges were plotted to give the between-laboratory precision profiles in Fig. 1 (for FSH) and Fig. 2 (for LH) . 30 the FSH scheme, and Table 2 the corresponding data in the LH scheme. For both analytes the CHW kit users consistently gave a lower variability of the bias, although this difference did not always reach statistical significance in the two 6-month periods reviewed. This lower variability of the bias is not due to the occurrence of a greater proportion of outlier results (which will often be excluded from the calculations of variability) among CHW kit users-for both FSH and LH, the 'own' method and CHW kit groups produced a similar percentage of within-laboratory outliers (2%). This implies that CHW kit users achieved better withinlaboratory, between-assay precision than users of 'own' methods. This was assessed from the variability of the bias statistic, which reflects the scatter of each laboratory's bias relative to the ALTM. Although several factors contribute to this statistic, e.g. dose-or pool-related changes in bias and possible instability of the ALTM, it provides a measure of within-laboratory, between-assay precision. Table 1 summarises the distribution of variability of the bias within method groups in compare (1) within-laboratory performance in each method group, (2) between-laboratory agreement within method groups, and (3) method-related bias.
Results

Data collected through the EQAS were used to
TABLE 3. FSH EQAS: cumulative mean bias ("!o)
relative to the ALTM for method groups over two consecutive 6-month periods significant difference in median bias between the 'own' method and CHW kit. As the ALTM in the LH scheme appears to overestimate the true value, possibly reflecting positive distortion by other kit methods included in the scheme, the negative median bias of the own and CHW kit methods is probably acceptable, although this does not in itself provide evidence for the kit's accuracy. 6 months to Oct. 1982 For both analytes, the CHW kit users had lower between-laboratory CVs across the entire concentration range, the differences being statistically significant in the low and normal ranges. This is not due to the occurrence among CHW kit users of a greater proportion of between-laboratory outliers (which are generally excluded from the calculation of betweenlaboratory CV). Indeed, the proportion of outliers among CHW kit users (0,8% for FSH and 1·1% for LH) was about half the corresponding proportion for 'own' method users (1·9% for FSH, 2·4% for LH).
METHOD-RELATED BIAS
Method-related bias was sought by comparing median cumulative bias for each of the method groups. For FSH (Table 3 ), median biases for the 'own' method and CHW kit users were not significantly different (Mann-Whitney U test), all being within ± 2·0% of the ALTM. In view of the evidence suggesting that the ALTM in the FSH scheme is accurate, these data are consistent with the 'own' methods and the CHW kit being accurate.
Similarly, for LH ( 
NS NS Discussion
An immunoassay method designed for general laboratory use has to satisfy certain initial analytical and practical criteria readily assessable as described previously. I However, objective long-term assessment of a kit's ability to meet these criteria in everyday use in a number of laboratories is a complex and timeconsuming activity. During initial method development and subsequently throughout the long-term production and use of the kits, in-house quality control will assure the manufacturers of the quality and consistency of the kit's performance. However, it is clear that data obtained in one centre, particularly an experienced and well-motivated one, may not necessarily be representative of the average user. Short-term collaborative trials involving a number of centres can yield further information On ruggedness but, in the long term the suitability, quality and consistency of a method kit can best be assessed by an independent external assessment scheme. Such an assessment can also provide information on the performance of a kit in comparison with other methods. In this study, data from the UK External Quality Assessment Scheme have been used to assess the long-term performance of a noncommercial kit in terms of method bias, withinlaboratory variability and between-laboratory agreement. The performance of the kit has been compared with the performance of laboratories using their own assay protocols, although often using some of the reagents incorporated in the kits.
The Chelsea (CHW) kit for LH and FSH radioimmunoassay appears to be sufficiently free from bias (insofar as this can be tested through EQAS) and to be sufficiently consistent and rugged to yield good within-laboratory reproducibility, and a significant improvement in between-laboratory agreement. These are important advantages which demonstrate the benefits to be derived from standardisation of reagents and assay protocols.
The performance of the FSH and LH kit represents the results of efforts spread over 14 years. It began with the ampouling of a reference serum in 1969, continued with the establishing of a discussion group of laboratories and an external quality control scheme in 1973 (initially within the Supraregional Assay Service but soon extended nationwide) and the provision of separate, ampouled reagents and recommended protocols from 1976. The kit itself has been available since March 1981.
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Four main difficulties associated with external quality-assessment schemes for hormones have been identified: paucity of data leading to sampling errors; misleading statistical evaluation and presentation of the data; unsuitability of the specimens; and uncertainty of bias evaluation because the true value is unknown or uncertain.
The Edinburgh EQAS has done much to limit, if not yet to eliminate, these problems. Firstly, the use of 6-month cumulative data minimises sampling errors by pooling information over a 6-month period. Short-term trends are not revealed but this should be the function of internal quality-control procedures, not external assessment. Secondly, the Edinburgh EQAS calculations are complex but they do represent a valid, and possibly the most suitable, approach to the reduction of a large amount of data to give clear messages. Thirdly, specimens should cover the dose range indicated by the clinical use of the methods (which should also have governed the design of the kit). Over the time period in question most specimens fell in the low-normal to moderately high regions. Data from outside this range are difficult to evaluate because laboratories often (with good reason) report 'less than' or 'greater than' values. Therefore the results obtained here should have the proviso attached that they have only been demonstrated over a particular dose range and may not be applicable to specimens with higher or lower analyte concentrations. Fourthly, the final problem, that of the suitability of the ALTM as a target value for calculating bias, is difficult to resolve satisfactorily. The accuracy of the AL TM has been assessed by recovery experiments in which known amounts of FSH (IRP 78/549) or LH (68/40) were added to serum pools. The AL TM appears to be sufficiently accurate for FSH, but may overestimate the 'true' value for LH. Users of the CHW kit for FSH have a median bias within 2·0% of the ALTM, suggesting that the kit provides accurate values. It is more difficult to assess the accuracy of the LH methods but the recovery experiments suggest that the ALTM may be positively biased. Thus the negative median biases of the 'own' and CHW kit methods may be acceptable.
A final question remains regarding the comparability of the laboratories in terms of expertise in radioimmunoassays. This is difficult to assess but, in general, the users of own assay protocols, whether using their own or the Chelsea reagents, tend to be in the more experienced centres than the users of either the CHW or commercial kits. This study shows that the users of the CHW kit, in which reagents are supplied with a carefully designed and tested protocol, perform better than centres using their own protocols, albeit with the same reagents in many cases. This is an important conclusion and illustrates the importance of a well-designed standardized protocol in the maintenance of assay quality.
Several factors appear to contribute to the success of the CHW kits. In the first place, high quality materials have been generously provided for the preparation of assay reagents. Secondly, laboratory staff from the Chelsea Hospital for Women have had considerable experience of the design and production of non-commercial kits through work for the WHO Special Programme in Human Reproduction. Thirdly, those producing the kit have been able to maintain close contact with users, to discuss and advise on problems where necessary. Finally, the design and production of a kit in a specialist postgraduate hospital using the assays extensively for both clinical and research purposes provides an important focus of expertise.
The success of this venture is not only scientific but also economic. The scheme is self-funding and the scale of its use is such that the National Health Service is saved a considerable sum annually. This should encourage other similar developments. The Chelsea Hospital for Women has already produced a 3-hour variant of the LH kit designed for immediate prediction of ovulation in the management of infertility and a prolactin assay kit has also recently been introduced.
